Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
LAGOON
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
- NCT05153239 ↗
- Completed
- PharmaMar
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on LAGOON yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LAGOON so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Relapsed Small Cell Lung Cancer
- Interventions
- Irinotecan; Lurbinectedin; Irinotecan; Topotecan; Lurbinectedin
- Arms
- Lurbinectedin · Experimental
- Lurbinectedin plus Irinotecan · Experimental
- Control arm · Active comparator
- Enrollment
- 705
- Primary outcomes
- Overall survival
- Sponsor
- PharmaMar
- Start
- Jul 22, 2022
- Primary completion
- Apr 10, 2026
- Results posted
- No
- Registry record
- NCT05153239 · updated Oct 21, 2026
Publications
linked from the registry- Falcon A, Ponce S, Cote GM, Gil A, Lin JJ, Bockorny B, Martinez J, Kahatt C, Martinez S, Zubiaur P, Siguero M, Cullell-Young M, Jimenez J, Zugazagoitia J, Paz-Ares L. Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors. Invest New Drugs. 2025 Aug;43(4):955-967. doi: 10.1007/s10637-025-01583-y. Epub 2025 Sep 18. PubMed 40963055